Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562499 | 0.88 | CHEK2 (0.68) | CHEK2SMN1; SMN2ALDH1A1KDM4ENPC1 | |
| SCHEMBL3560900 | 0.86 | CHEK2 (0.68) | CHEK2SMN1; SMN2ALDH1A1KDM4ERAB9A | |
| SCHEMBL3571725 | 0.84 | CHEK2 (0.68) | CHEK2SMN1; SMN2ALDH1A1KDM4ERAB9A | |
| SCHEMBL3915297 | 0.84 | MAPT (0.77) | CHEK2SMN1; SMN2ALDH1A1KDM4ENPC1 | |
| SCHEMBL5177628 | 0.83 | CHEK2 (0.72) | CHEK2ALDH1A1CNR1SLC2A1TSHR | |
| SCHEMBL3571821 | 0.83 | CHEK2 (0.86) | CHEK2TSHR | |
| SCHEMBL10466041 | 0.82 | CNR1 (0.62) | CHEK2SMN1; SMN2ALDH1A1KDM4ENPC1 | |
| SCHEMBL3574951 | 0.81 | CHEK2 (0.73) | CHEK2SMN1; SMN2ALDH1A1MAPTCYP19A1 | |
| SCHEMBL3571768 | 0.81 | CHEK2 (0.71) | CHEK2SMN1; SMN2ALDH1A1KDM4ECNR1 | |
| SCHEMBL2242715 | 0.80 | NPC1 (1.00) | SMN1; SMN2ALDH1A1KDM4ENPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687639-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | BW CONVERTING AB (SE) | 2006-11-09 | — | — | US | disclosed |
| US-7132440-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDKN1A, DDB1, TMBIM6 | CHEK2 14/4885SMN1; SMN2 3372/4885ALDH1A1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.